Drug Trial Radar · NCT03361748
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Dec 13, 2017
Primary completion
Dec 20, 2023
Study completion Dec 20, 2023
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Conditions
- Multiple Myeloma
Interventions
bb2121Biological
: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: From first dose to 24 Months
Locations
48 sites in 8 countries. Site status is shown where the registry gives one.
Local Institution - 108
San Francisco, California
University of California - San Francisco
San Francisco, California
Emory University
Atlanta, Georgia
Local Institution - 103
Atlanta, Georgia
Local Institution - 107
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Local Institution - 106
Boston, Massachusetts
Local Institution - 105
Rochester, Minnesota
Mayo Clinic
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Local Institution - 102
Hackensack, New Jersey
Local Institution - 109
New York, New York
Mt. Sinai Medical Center
New York, New York
Local Institution - 101
Nashville, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
Local Institution - 104
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Local Institution - 201
Leuven, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Flemish Brabant, Belgium
Princess Margaret Cancer Centre
Toronto, Canada
Local Institution - 301
Toronto, Ontario, Canada
Local Institution - 402
Lille, France
Local Institution - 401
Nantes, France
Centre Hospitalier Regional Universitaire de Lille-Hopital Calude Huriez Service des Maladies du Sang
Lille, Hauts-de-France, France
Centre Hospitalier Universitaire de Nantes - Hotel Dieu
Nantes, Pays de la Loire Region, France
Local Institution - 502
Heidelberg, Germany
Local Institution - 503
Tübingen, Germany
Local Institution - 501
Würzburg, Germany
Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato
Heidelberg, Baden-Wurttemberg, Germany
University of Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universitatsklinikum Würzburg
Würzburg, Bavaria, Germany
Local Institution - 602
Bergamo, Italy
Ospedali Riuniti di Bergamo
Bergamo, Italy
Local Institution - 601
Bologna, Italy
Azienda Ospedaliero Universitaria Di Bologna Policlinico
Bologna, Emilia-Romagna, Italy
Local Institution - 803
Isehara City, Kanagawa, Japan
Local Institution - 801
Shibuya-ku, Japan
Local Institution - 802
Shimotsuke, Japan
Local Institution - 804
Shinjuku, Japan
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.